Nuvation Bio Pipeline Presentation February 2024

Nuvation Bio presents its oncology drug candidate pipeline featuring wholly-owned programs targeting unmet needs across advanced solid tumors, metastatic breast cancer, and prostate cancer. The company highlights progress on NUV-868, a BET inhibitor in Phase 1/1b studies, and NUV-1511, a drug-drug conjugate with IND clearance anticipated to initiate Phase 1/2 development in 1H 2024.